MXPA01011606A - Anti-inflammatory therapy for inflammatory mediated infection. - Google Patents

Anti-inflammatory therapy for inflammatory mediated infection.

Info

Publication number
MXPA01011606A
MXPA01011606A MXPA01011606A MXPA01011606A MXPA01011606A MX PA01011606 A MXPA01011606 A MX PA01011606A MX PA01011606 A MXPA01011606 A MX PA01011606A MX PA01011606 A MXPA01011606 A MX PA01011606A MX PA01011606 A MXPA01011606 A MX PA01011606A
Authority
MX
Mexico
Prior art keywords
inflammatory
therapy
mediated infection
progression
inhibiting
Prior art date
Application number
MXPA01011606A
Other languages
Spanish (es)
Inventor
Michael A Poles
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MXPA01011606A publication Critical patent/MXPA01011606A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Provided are methods for inhibiting the progression of an inflammatory mediated mucosal infection. The methods include administering an effective amount of an anti-inflammatory agent. Also provided are compositions and articles of manufacture for preventing, and inhibiting the activation and progression of a mucosal infection.
MXPA01011606A 1999-05-14 2000-05-12 Anti-inflammatory therapy for inflammatory mediated infection. MXPA01011606A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13409199P 1999-05-14 1999-05-14
PCT/US2000/013142 WO2000069255A1 (en) 1999-05-14 2000-05-12 Anti-inflammatory therapy for inflammatory mediated infection

Publications (1)

Publication Number Publication Date
MXPA01011606A true MXPA01011606A (en) 2003-09-10

Family

ID=22461735

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01011606A MXPA01011606A (en) 1999-05-14 2000-05-12 Anti-inflammatory therapy for inflammatory mediated infection.

Country Status (13)

Country Link
EP (1) EP1202620A1 (en)
JP (1) JP2002544210A (en)
KR (1) KR20020024587A (en)
CN (1) CN1353573A (en)
AU (1) AU5010800A (en)
BR (1) BR0010546A (en)
CA (1) CA2368593A1 (en)
HK (1) HK1047216A1 (en)
IL (1) IL146130A0 (en)
MX (1) MXPA01011606A (en)
PL (1) PL351710A1 (en)
TR (1) TR200103271T2 (en)
WO (1) WO2000069255A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1303265E (en) * 2000-07-20 2007-10-09 Lauras As Use of cox-2 inhibitors as immunostimulants in the treatment of hiv or aids
MXPA04006572A (en) * 2002-01-10 2005-11-04 Upjohn Co Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections.
AR039540A1 (en) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd MICROBICIDE COMPOUNDS WITH PIRIMIDINE OR TRIAZINE CONTENT
US6790867B2 (en) * 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
AU2003261304A1 (en) 2002-07-30 2004-02-16 Omeros Corporation Ophthalmologic irrigation solutions and method
ITMI20031311A1 (en) * 2003-06-27 2004-12-28 Indena Spa FORMULATIONS FOR THE TREATMENT OF ARTHROSIC DISORDERS.
ZA200604253B (en) * 2003-11-21 2007-10-31 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
CN102002476B (en) * 2010-08-20 2013-05-08 上海市公共卫生临床中心 Human mucous membrane living tissue model cultured in vitro as well as building method and application thereof
CN102557976B (en) * 2010-12-15 2015-06-10 辽宁盛京制药有限公司 Bromfenac organic salt, and preparation method thereof, composition thereof and application thereof
EP2481751A1 (en) * 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Human lactoferrin derived peptides
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
CN104013959A (en) * 2014-05-21 2014-09-03 郭和友 Reverse transcription inhibitor, immunity and antibody cell three-combined therapy
CN105456273A (en) * 2014-09-02 2016-04-06 杭州雷索药业有限公司 Application of nevirapine in preparing anti-inflammatory medicine
TWI705812B (en) 2014-12-01 2020-10-01 奥默羅斯公司 Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
CN106309445A (en) * 2016-08-18 2017-01-11 滨州医学院 New medical application of Nelfinavir to enhancement of anti-inflammatory action of glucocorticoid
CN106176739A (en) * 2016-08-18 2016-12-07 滨州医学院 Ritonavir strengthens the new medical use of glucocorticoid antiinflammatory action
CN106176751A (en) * 2016-08-18 2016-12-07 滨州医学院 Indinavir strengthens the new medical use of glucocorticoid antiinflammatory action

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605885A (en) * 1988-05-05 1997-02-25 Entremed, Inc. Method for stimulating the immune system
EP0407701A3 (en) * 1989-05-15 1992-04-22 Fujisawa Pharmaceutical Co., Ltd. Antiretroviral pyrroline and pyrrolidine sulfonic acid derivatives
US5891924A (en) * 1996-09-26 1999-04-06 Research Development Foundation Curcumin (diferuloylmethane) inhibition of NFκB activation

Also Published As

Publication number Publication date
WO2000069255A8 (en) 2001-03-22
IL146130A0 (en) 2002-07-25
BR0010546A (en) 2002-03-05
HK1047216A1 (en) 2003-02-14
CN1353573A (en) 2002-06-12
PL351710A1 (en) 2003-06-02
AU5010800A (en) 2000-12-05
EP1202620A1 (en) 2002-05-08
KR20020024587A (en) 2002-03-30
CA2368593A1 (en) 2000-11-23
WO2000069255A1 (en) 2000-11-23
JP2002544210A (en) 2002-12-24
TR200103271T2 (en) 2002-06-21

Similar Documents

Publication Publication Date Title
MXPA01011606A (en) Anti-inflammatory therapy for inflammatory mediated infection.
BG106586A (en) Pyrazolopyramidines as therapeutic agents
AU7031500A (en) Therapeutic quinazoline compounds
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
EP1352897A3 (en) Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
AU2002356759A1 (en) 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
ZA200301269B (en) Prodrugs of betulinic acid derivatives for the treatment of cancer and HIV.
WO2002080890A3 (en) A jasmonate pharmaceutical composition for treatment of cancer
HN2001000244A (en) SPIROPIRIMIDIN INHIBITORS - 2, 4, 6 - TRIONA METALOPROTEINASAS.
MXPA03010761A (en) Pharmaceutical combinations.
CY1107465T1 (en) MELAGATRANI FOR THERAPEUTIC INFECTION
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
IS6130A (en) Anti-inflammatory treatment for inflammation associated with infection
AU2732597A (en) Novel pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
NZ514558A (en) Viral treatment
GB9907571D0 (en) Compounds
IL153540A0 (en) THE USE OF 7beta-HYDROXY-STEROID DERIVATIVES FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS
MXPA03001081A (en) Anti-inflammatory medicament.
AP9801202A0 (en) Atropisomers of 3-heteroaryl-4(3H)-quinazolinones.
ZA979647B (en) Heterocyclic compounds, compositions and uses.
NZ515685A (en) Use of riluzole for the treatment of multiple sclerosis
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
IL153541A0 (en) The use of 7-hydroxyepiandrosterone for the manufacture of pharmaceutical compositions
WO2000069841A3 (en) Benzofuranylaminoalcohols
ZA979650B (en) Heterocyclic compounds, compositions and uses.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal